Thursday, October 8, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 29, 2026

Honeywell (HON) Q4 2025 Earnings Call Transcript

View original at finance.yahoo.com
Honeywell (HON) Q4 2025 Earnings Call Transcript Image source: The Motley Fool. DATE Thursday, January 29, 2026 at 8:30 a.m…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We exited the year with a sales growth of 6% excluding the impact of the 2024 Bombardier agreement, which demonstrates the outcome of our portfolio actions and our emerging focus on innovation stemming from continued investment in R&D

    80% confidence
  • Honeywell is close to capacity with Department of Defense with minimal past-due deliveries

    80% confidence
  • Next quantum machine committed for 2027 timeframe

    80% confidence
  • Vitality index for RemainCo Honeywell is high 40s, approximately 45%

    80% confidence
  • Multiple ongoing commercial OE contract negotiations with 5-7+ year terms expected to have positive long-term impact on Aerospace margins

    80% confidence
  • Fundamentally, the inflationary trend in industrial segment and segments per Honeywell Surf they remain quite persistent... 2026 is gonna look very similar to 2025 in the same ZIP code

    80% confidence
  • R&D investment level of 4.4-4.8% of sales considered the sweet spot with majority focused on new product development versus upgrades

    80% confidence
  • Honeywell Forge Building Automation is 9-12 months ahead of Process Connected Plant offering in IoT platform development

    80% confidence
  • Aerospace stranded costs elimination expected 12-18 months post-spin

    80% confidence
  • Operationally, we really are expanding margins about 50 to 90 basis points

    80% confidence
  • Supply chain delivered 14 consecutive quarters of double-digit volume growth in Aerospace

    80% confidence
  • This collaboration between QuantiNUM and NVIDIA is creating a future where AI becomes more expansive through quantum computing, and quantum computing becomes more powerful through AI

    80% confidence
  • Petrochemical catalysts experiencing continued project deferrals due to excess global capacity and customer reluctance

    80% confidence
  • Data centers approaching more than 5% of Building Automation revenue

    80% confidence
  • We have built now a business in industrial automation, which is heavily focused on sensing and measurement

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com